alexa Implications of High Grade Lymphoma Arising in Chronic Myeloid Leukaemia | OMICS International
ISSN: 2329-6917
Journal of Leukemia
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Implications of High Grade Lymphoma Arising in Chronic Myeloid Leukaemia

David Paul Busuttil*

Consultant Haematologist, Mater Dei Hospital, Malta, UK

*Corresponding Author:
Dr. David Paul Busuttil, MD MSc FRCP FRCPath
Consultant Haematologist, Mater Dei Hospital, Malta, UK
Tel: 21313692, 25456348
E-mail: [email protected]

Received date: July 16, 2015 Accepted date: July 30, 2015 Published date: August 07, 2015

Citation: Busuttil DP (2015) Implications of High Grade Lymphoma Arising in Chronic Myeloid Leukaemia. J Leuk (Los Angel) S1:003. doi: 10.4172/2329-6917.S1-003

Copyright: © 2015 Busuttil DP, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Leukemia

Letter to the Editor

There have been several reports of different types of Philadelphia (Ph) negative lymphomas arising in chronic myeloid leukaemia (CML) [1-5]. These are usually of T- cell origin but also include B- cell lymphomas ranging from mantle cell lymphoma, follicular lymphoma and diffuse large B- cell lymphoma(DLBCL).These however have all been described in the pre- tyrosine kinase (TKI) era and the lymphomas have been of extramedullary origin.

I present the case of a 64 year old man with CML who had achieved a major molecular response after one year of imatinib therapy. He then presented with cachexia and obstructive jaundice.The blood count was stable WBC 2.9 × 109 Neutrophils 1.1 × 109/l Hb 11.4 g/l Platelets 241 × 109/l. The BCR/ABL ratio was 0.4% on a marrow sample. The bilirubin was 97 umol/l GGT 1182 U/l ALT 242 U/l ALK 1320 U/l. Liver and spleen metastases, multiple skeletal lytic lesions, mesenteric and paraortic lymphadenopathy were detected on CT scan. There were also bilateral pleural effusions and he later developed gross ascites. The marrow architecture was completely effaced by a diffuse infiltrate of immature lymphoma cells. The liver biopsy revealed infiltration by DLBCL and lymphoma cells were present in the pleural fluid. The lymphoma cells in the marrow demonstrated the t 2:18 and there was no evidence of t 9:22 by FISH. A diagnosis of denovo stage IV DLBCL with marrow involvement was made.

The patient therefore had two unrelated malignancies even though prima facie the presentation was typical of a lymphoid transformation of CML. It is well known that TKI therapy can select resistant clones and a focal clonal escape from the original CML population in the marrow resulting in the lymphoma could have occurred. If this were a lymphoid transformation, the TKI would have had to be changed to a more potent TKI besides inducing with acute leukaemia- type therapy and backing this up with an allogeneic stem cell transplant. However, since these were two distinct malignancies, imatinib was continued and the lymphoma was treated with R-HyperCVAD/MA although the patient eventually succumbed.

A hypothesis is that a) the original malignant clone had arisen in a very early cell not committed to either lineage b) that part of the clonal population had acquired a t 9:22 and had then undergone differentiation to develop myeloid characteristics consistent with CML c) that another part of the original clone had acquired the t 2:18 and subsequently differentiated along the lymphoma route.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11775
  • [From(publication date):
    specialissue-2015 - Jun 20, 2018]
  • Breakdown by view type
  • HTML page views : 8008
  • PDF downloads : 3767

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7